Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial

Alexander Blood; Lee‐Shing Chang; Shahzad Hassan; Jacqueline Chasse; Gretchen Stern; Daniel Gabovitch; David Zelle; Caitlin Colling; Samuel Aronson; C.E. Alcántara-Figueroa; Emma Collins; Ryan Ruggiero; Emily Zacherle; Joshua Noone; Carey Robar; Jorge Plutzky; Thomas A. Gaziano; Christopher P. Cannon; Deborah J. Wexler; Benjamin M. Scirica

doi:10.1161/circulationaha.124.069494

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Several SGLT2i (sodium-glucose transport protein 2 inhibitors) and GLP1-RA (glucagon-like peptide-1 receptor agonists) reduce cardiovascular events and improve kidney outcomes in patients with type 2 diabetes; however, utilization remains low despite guideline recommendations.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Blood et al. (2024) studied this question.

synapsesocial.com/papers/68e701efb6db64358767b84b https://doi.org/10.1161/circulationaha.124.069494

View at Publisher

Ask AI

Bookmark

Share

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Randomized Evaluation of a Remote Management Program to Improve Guideline-Directed Medical Therapy: The DRIVE Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading